Article Text

Download PDFPDF

Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
Free
  1. Leonard Calabrese1,
  2. Vamsidhar Velcheti2
  1. 1Department of Rheumatology/Immunology, Cleveland Clinic, Cleveland, Ohio, USA
  2. 2Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio, USA
  1. Correspondence to Dr Leonard Calabrese, Department of Rheumatology/Immunology, Cleveland Clinic, 9500 Euclid Drive, Cleveland, OH 44106, USA; calabrl{at}ccf.org

Statistics from Altmetric.com

The goal of harnessing the immune system to fight cancer is not new; it dates back 125 years to when William Coley advocated that the body's response to infection could have anti-tumoural effects.1 However, decades of efforts using vaccines and immune stimulant therapies to harness the immune system to fight tumours have had limited success and at times have been fraught with serious adverse outcomes. Recently, drugs blocking negative immune checkpoint pathways have shown remarkable clinical activity in various solid tumours.2 Several agents targeting two such negative checkpoints, the programmed death-1 (PD-1) pathway (pembrolizumab, nivolumab and atezolizumab) and the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (ipilimumab) are currently Food and Drug Administration and European Medicines Agency approved. These negative checkpoint pathways play a role in immune tolerance in normal tissues and the activation of these pathways is largely contextual. While these therapies have added immeasurably to the longevity of many patients with malignancies, they have come at a cost with the development of numerous untoward autoimmune inflammatory conditions.

The anti-tumour mechanism for checkpoint inhibitor therapies is incompletely understood but clearly relates to the manipulation of T-cell pathways involved in cellular activation and deactivation.2 T-cell homeostasis is a tightly choreographed process whereby naïve T cells rapidly proliferate in a logarithmic fashion when effectively activated and then contract following successful defeat of the challenge. CD4 T-cell activation canonically requires two signals: a primary signal (signal 1), mediated by recognition of cognate antigen by the T-cell receptor via presentation by self-major histocompatibility complex class II molecules on the antigen-presenting cell, and a secondary signal (signal 2), mediated by CD28 on the T-cell, binding its ligand partner of the B7 family on the antigen-presenting cell.3 Of vital importance to the host is the integration of deactivating pathways or checkpoints leading to contraction …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Clinical and epidemiological research
    Laura C Cappelli Anna Kristina Gutierrez Alan N Baer Jemima Albayda Rebecca L Manno Uzma Haque Evan J Lipson Karen B Bleich Ami A Shah Jarushka Naidoo Julie R Brahmer Dung Le Clifton O Bingham III